WellDoc Announces Formation of Scientific Advisory Team

WellDoc Announces Formation of Scientific Advisory Team

March 22, 2018

Columbia, Maryland, March 22, 2018 – WellDoc®, a leading digital therapeutic company, announces today the formation of its scientific advisory team whose expertise spans cardiology, health behavior, endocrinology, primary care and pharmacy-based diabetes education and care. Richard Katz, MD, Janet Duni, RN, BSN, MPA, CCM, Pablo Mora, MD, Nancy D’Hondt, RPh, CDE, FAADE, Edwin Fisher, PhD and Charlene Quinn, PhD have each been involved in WellDoc’s digital health journey with product enhancement, evaluation, or implementation and have been asked to now formally serve as scientific
advisors to the company.

“WellDoc is fortunate to have such an impressive group of scientific advisors who have been instrumental in working with WellDoc,” said WellDoc President and CEO Kevin McRaith. “We look forward to continuing to draw on their expertise, as we enhance our product, BlueStar, for individuals living with type 2 diabetes, as well as move into other disease states such as hypertension, which will be available soon.”

Dr. Katz is currently the Director of the Division of Cardiology and the Heart and Vascular Institute and the Bloedorn Professor of Cardiology at the George Washington University School of Medicine. He has been an author or coauthor on over 100 manuscripts and more than 100 abstracts. Dr. Katz recently completed a three-year $2,000,000 project funded by the Patient Centered Outcomes Research Institute, comparing diabetes outcomes assisted by mHealth alone, community health workers alone and the combination of both. Dr. Katz conducted two projects with WellDoc that include a real-world demonstration project in an inner-city Medicaid population and a mobile health hypertension project funded by the McKesson Foundation. He is advising WellDoc on the development of WellDoc’s hypertension solution.

As the Director of Care Coordination at Vanguard Medical Group, Ms. Duni provides expertise in the creation of population health strategies and driving patient engagement through value-based initiatives with Centers for Medicare and Medicaid Services (CMS), Account Care Organizations (ACOs) and commercial payer programs. Over the past seven years, she has led a team of nurses and support staff in a robust and innovative care coordination program, which has directly supported patient care efficacy and the financial goals of the practice. Ms. Duni participated in the Vanguard Peer Coach-Digital Health Study with WellDoc to assess care coordination models with digital health. She continues to provide expertise for digital health integration in evolving primary care practices.

Dr. Mora is a Certified Diabetes Educator with a background in endocrinology, internal medicine, critical care and clinical sciences. He is an adjunct professor at the University of Texas Southwestern Medical School and an associate editor for the American Diabetes Association’s journal, Clinical Diabetes. In 2017, Dr. Mora joined the Dallas Diabetes and Endocrinology Center and Dallas Diabetes Research Center. Recently, he implemented a model for effective care of transitional patients (pediatric to adult) with diabetes, as well as worked on the delineation of certain business models to deliver effective diabetes care in current healthcare environments. Currently, Dr. Mora is working with WellDoc in the development of WellDoc’s Type 1 diabetes solution and other product enhancements.

Ms. D’Hondt is as a Certified Diabetes Educator and clinical pharmacist at St. John Hospital. In 2017, she was president of the American Association of Diabetes Educators (AADE) president and is a fellow of the AADE. She has served with American Diabetes Association on their National Advocacy committee and as associate editor for Clinical Diabetes. During her tenure as president with AADE, she collaborated with WellDoc to launch the Diabetes Digital Health Learning Network to engage innovative educators in integrating digital health into practice.

Dr. Fisher specializes in health behavior as a public health professional, researcher and clinical psychologist at the University of North Carolina Gillings School of Public Health. His research focuses on the behavioral patterns experienced by people in chronic disease prevention, management and quality of life. He currently serves as the Global Director of Peers for Progress, a program that documents the benefits of peer support in diabetes management and conducts diverse activities to promote peer support around the world. Dr. Fisher partnered with WellDoc, Vanguard Medical Group and Horizon to test the feasibility and reach of integrating health coaches with BlueStar in a Patient-Centered Medical Home (PCMH).

Dr. Quinn is an experienced geriatric nurse, with training from Duke University, University of Maryland, and Johns Hopkins School of Hygiene and Public Health. A former White House Fellow and senior Federal executive she has extensive government, business, and research experience in gerontology, health policy and health delivery technologies. She is a former board member of the largest publically traded long-term care services company. The focus of her funded research is the development of new approaches to the treatment of chronic diseases and conditions common among older adults. She has been recognized by the Director of NIH as a pioneer in behavior science research. Dr. Quinn’s research team conducted WellDoc’s randomized clinical trials of mobile (phone) diabetes management and continues to collaborate with WellDoc for ongoing research.

“From the beginning, WellDoc has been committed to pursuing a rigorous science journey and developing evidence-based interventions,” said WellDoc Vice President of Clinical Services, Programsand Research Malinda Peeples, RN, MS, CDE. “We are pleased to be working with these scientific advisors as we continue expanding our product line and working with diverse implementation models.”

About BlueStar®

BlueStar®, powered by WellDoc®, is an FDA-cleared, proven digital therapeutic that is an in-app coach engaging people with type 2 diabetes. It delivers personalized, real-time feedback, as well as diabetes educational tools that are actionable and individualized. Specifically, WellDoc has developed more than 30 peer-reviewed publications and presentations on BlueStar, including two randomized, controlled clinical trials. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. BlueStar delivers an estimated average cost savings of $254-$271 per user per month, proven clinical outcomes and a net promoter member satisfaction score of 70. For more information on BlueStar, visit: www2.bluestardiabetes.com.

This year, Samsung Electronics America, Inc. and WellDoc announced that Samsung Health users now have access to a new consumer version of WellDoc’s digital platform known as the Diabetes Wellness Program (DWP). The DWP, which is integrated within the Samsung Health service, is a 12-week health and wellness program designed to help adults with type 2 diabetes achieve a healthy lifestyle and to help manage their condition.

About WellDoc®

WellDoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of helping individuals self-manage their conditions to achieve significant clinical outcomes and cost savings. We began our journey by mastering diabetes management solutions and are moving rapidly into creating additional tools for managing other chronic diseases including hypertension, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have taken an aggressive and innovative approach that utilizes sophisticated logic, precise algorithms, and artificial intelligence (AI), which integrates the most advanced mobile technology and behavioral insights. WellDoc partners with, collaborates with, and is backed by top healthcare companies (including Merck and Johnson and Johnson), leading innovators, dedicated investors, and top mobile technology
companies (such as Samsung). For more information, visit www.welldoc.com.